IPA (ImmunoPrecise) Earnings per share growth rate in current year
ImmunoPrecise Antibodies (IPA) leads in AI-driven antibody creation, accelerating target discovery and expanding its partnership network. High demand for computational screening fuels current growth while new catalysts mature. A technological moat and patent protection distinguish the company from traditional laboratories. The year-over-year EPS percentage deviation confirms the success of the model, where the 83.10 indicator determines the metric's magnitude.
Financial and market metric breakdowns for immunoprecise.com (IPA)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient ImmunoPrecise Antibodies|IPA - Long-Term Debt to Capital|Current Liabilities to Capital ImmunoPrecise Antibodies Ltd.|IPA - Company Total Debt|Debt to Net Assets Ratio ImmunoPrecise Antibodies Ltd.|IPA - Company Long-Term Debts|Company Short-Term Debts ImmunoPrecise Antibodies|Immediate Liquidity Ratio immunoprecise.com
- net income and valuation ratios data:
IPA - Net Income|Future Net Profit ImmunoPrecise Antibodies|IPA - P/E Multiple|Market Cap to Projected Earnings ImmunoPrecise Antibodies Ltd.|IPA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmunoPrecise Antibodies Ltd.|IPA - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months ImmunoPrecise Antibodies|IPA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months immunoprecise.com|IPA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year ImmunoPrecise Antibodies
Summary company analysis:ImmunoPrecise (IPA)
Analyzing earnings per share (EPS) growth relative to the previous year is critical for finding the balance between business quality and market valuation. This metric measures net income growth rates, determining real capital efficiency and a company's resilience to market shocks. In the case of ImmunoPrecise Antibodies (IPA), high B2B customer loyalty driven by AI integrations ensures the stability of this growth, which is clearly evidenced by tracking annual EPS growth.
Direct competitors
Tempus Labs - Earnings per share increase in current year|QGEN (Qiagen Group) - Earnings growth in current year|Earnings per share growth rate in current year Isis Pharmaceuticals IONS|Earnings growth in current year RGEN|Net earnings per share growth this year aviditybiosciences.com RNA|Earnings growth in current year CRSP (CRISPR Therapeutics)|Expected net earnings per share growth this year GeneDx Holdings (WGS)|RARE - Earnings per share growth in current year|Expected net earnings per share growth this year Beam Tx BEAM|SRPT: Earnings growth in current year|Earnings per share growth rate in current year twistbioscience.com (TWST)|Net earnings per share growth this year TXG|NTLA: Earnings per share increase in current year|Earnings growth in current year STOK|Earnings growth in current year BioLife (BLFS)|Earnings per share growth in current year Wave Life Sciences WVE|MAZE: Earnings per share growth this year|SION: Net earnings per share growth this year|Prime Medicine Inc - Net earnings per one share growth for the current year|TSHA: Earnings growth in current year|QURE - Expected net earnings per share growth this year|MGTX (MeiraGTx Holdings plc) - Earnings growth in current year|Earnings per share growth in current year RGNX|Earnings per share growth in current year Solid Biosciences (SLDB)|OCGN - Earnings per share growth rate in current year|Earnings growth in current year PACB (Pacific Biosciences of California)|BNTC: Earnings per share growth this year|Design Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year rocketpharma.com RCKT|FDMT: Earnings growth in current year|Earnings per share growth rate in current year Lexeo Therapeutics, Inc. (LXEO)|Earnings per share growth in current year Korro Bio Inc.|Editas Corp (EDIT) - Expected net earnings per share growth this year|Earnings growth in current year SLN|Expected net earnings per share growth this year proqr.com|Earnings per share growth in current year Codexis CDXS|SGMO (Sangamo Therapeutics Inc.) - Earnings per share trend in current year|Nautilus Biotechnology Inc - Earnings growth in current year|MGX - Earnings growth in current year|DTIL: Earnings growth in current year|Earnings per share growth this year GBIO|Earnings per share growth in current year Boundless Bio|Earnings per share growth this year XCUR (Exicure Corp)|Earnings growth in current year IMNN|Earnings growth in current year phiopharma.com (PHIO)|Earnings growth in current year MBIO (Mustang Bio)|Expected net earnings per share growth this year TransCode Therapeutics Inc. (RNAZ)|BNGO - Earnings per share growth in current year|Applied DNA Sciences Inc (APDN) - Net earnings per share growth this year|Bluebird Bio (BLUE) - Earnings per share growth in current year|Net earnings per share growth this year Omega Therapeutics Corp|Net earnings per share growth this year OMIC|Earnings growth in current year regulusrx.com|Earnings per share growth in current year Syros Pharmaceuticals, Inc. (SYRS)|Telesis Bio Inc. - Earnings per share growth this year|Earnings per share growth in current year TRACON TCON|Unity Biotechnology, Inc (UBX) - Earnings per share growth rate in current year
